Presentations will be CME accredited, and it is therefore essential that they be free from commercial influence. Please read the Product Name Use Policy below for further details.
All presentations must clear a review conducted by the SRS CME Committee. Faculty are required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found. Faculty presentations should be submitted to email@example.com starting March 21, 2018. All faculty presentations must be submitted for CME review by Monday, June 4, 2018.
Failure to address pertinent CME review issues will result in removal of the presentation from the program and/or a one-year ban for abstract presentations and a three-year ban for invited presentations.
Please note that an additional slide including all authors' financial disclosures will be shown on the screen opposite of the presenter during the presentation. If speakers have any corrections to make to their disclosure statement, please send them to firstname.lastname@example.org by May 1, 2018.
Product Name Use Policy *NEW UPDATED POLICY*
SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque).
Company names and logos must never be used in a presentation (including in images.)
It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, an expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.